Stifel analyst Rick Wise lowered his price target on LivaNova to $100 after its soft Q1 pre-announcement driven by “more intense FX headwinds”, challenges in the U.S. Neuromodulation segment, and the ongoing execution issues at Perceval pressuring the company’s Heart Valves sales by 11.4%. Longer term, the analyst is keeping his Buy rating on LivaNova however, citing its “dramatic and positive transformation” over the past 18 months with the divestiture of the lower-margin Cardiac Rhythm Management business and the hiring of a new and experienced management team. Wise believes that the company has the “solid foundation” to grow its revenue and earnings while supporting its “growth-enhancing pipeline investments.”
https://thefly.com/landingPageNews.php?id=2889327
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.